Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 4/20 | 0.53 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.53 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.53 |
| ▸ | HTR2A | P28223 | 2/20 | 0.53 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | PPARA | Q07869 | 1/20 | 0.46 |
| ▸ | SLC1A5 | Q15758 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.41 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.39 |
| ▸ | PNLIP | P16233 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9995320 | 0.89 | SLC6A4 (0.52) | SLC6A4SLC6A2SLC6A3HTR2AMEN1 | |
| SCHEMBL10093029 | 0.86 | L3MBTL1 (0.44) | SLC6A4SLC6A2SLC6A3HTR2AMEN1 | |
| SCHEMBL8471261 | 0.85 | SLC6A4 (0.58) | SLC6A4SLC6A2SLC6A3HTR2AMEN1 | |
| SCHEMBL2248000 | 0.85 | HTR2A (0.60) | SLC6A4SLC6A2SLC6A3HTR2AMEN1 | |
| SCHEMBL878121 | 0.85 | SLC6A4 (0.47) | SLC6A4SLC6A2SLC6A3HTR2AMEN1 | |
| SCHEMBL13474499 | 0.83 | SLC6A4 (0.53) | SLC6A4SLC6A2SLC6A3HTR2AMEN1 | |
| SCHEMBL12361548 | 0.82 | SLC6A4 (0.54) | SLC6A4SLC6A2SLC6A3HTR2APPARA | |
| SCHEMBL13752339 | 0.80 | L3MBTL1 (0.43) | SLC6A4HTR2AMEN1KMT2APOLB | |
| SCHEMBL28801696 | 0.79 | PPARA (0.54) | SLC6A4SLC6A2SLC6A3HTR2APPARA | |
| SCHEMBL12353135 | 0.78 | SLC6A4 (0.50) | SLC6A4SLC6A2SLC6A3HTR2APPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2012038975-A2 | PROCESS FOR THE PREPARATION OF (3ARS,12BRS)-5-CHLORO-2-METHYL-2,3,3A12B-TETRAHYDRO-1HDIBENZO[2,3:6,7] OXEPINO [4,5-C]PYRROLE MALEATE AND IT'S PHARMACEUTICAL COMPOSITION THEREOF | MSN LABORATORIES LIMITED (IN) | 2012-03-29 | — | — | WO | claimed |
| EP-2468751-B1 | Processes for the preparation of 5-chloro-2-methyl-2,3,3a,12b-tetrahydro-1H-dibenzo[2,3:6,7]oxepino[4,5-c]pyrrole | MEDICHEM SA (ES) | 2016-03-16 | — | — | EP | disclosed |
| EP-2468751-B1 | Processes for the preparation of 5-chloro-2-methyl-2,3,3a,12b-tetrahydro-1H-dibenzo[2,3:6,7]oxepino[4,5-c]pyrrole | MEDICHEM SA (ES) | 2016-03-16 | — | — | EP | disclosed |
| US-8779161-B2 | Asenapine maleate | DR. REDDY'S LABORATORIES LIMITED (IN) | 2014-07-15 | — | — | US | disclosed |
| US-8580972-B2 | Processes for the preparation of 5-chloro-2-methyl-2,3,3A,12b-tetrahydro-1H-dibenzo[2,3:6,7]oxepino[4,5-c]pyrrole | MEDICHEM, S.A. (ES) | 2013-11-12 | — | — | US | disclosed |
| US-8580972-B2 | Processes for the preparation of 5-chloro-2-methyl-2,3,3A,12b-tetrahydro-1H-dibenzo[2,3:6,7]oxepino[4,5-c]pyrrole | MEDICHEM, S.A. (ES) | 2013-11-12 | — | — | US | disclosed |
| US-8580972-B2 | Processes for the preparation of 5-chloro-2-methyl-2,3,3A,12b-tetrahydro-1H-dibenzo[2,3:6,7]oxepino[4,5-c]pyrrole | MEDICHEM, S.A. (ES) | 2013-11-12 | — | — | US | disclosed |
| US-20130211099-A1 | ASENAPINE MALEATE | DR. REDDY'S LABORATORIES, INC. (US) | 2013-08-15 | — | — | US | disclosed |
| WO-2013061247-A1 | NOVEL PROCESS FOR THE PREPARATION OF ASENAPINE | ALEMBIC PHARMACEUTICALS LIMITED (IN) | 2013-05-02 | — | — | WO | disclosed |
| US-8426610-B2 | Intermediate compounds for the preparation of trans-5-chloro-2-methyl-2,3,3a,12b-tetrahydro-1H-dibenz[2,3:6,7]-oxepino[4,5-c]pyrrole | MERCK SHARP & DOHME B.V. (NL) | 2013-04-23 | — | — | US | disclosed |
| US-7872147-B2 | Intermediate compounds for the preparation of trans-5-chloro-2-methyl-2,3,3a,12b-tetrahydro-1H-dibenz[2,3:6,7]oxepino[4,5-c]pyrrole | N. V. ORGANON (NL) | 2011-01-18 | — | — | US | disclosed |
| US-20100152461-A1 | INTERMEDIATE COMPOUNDS FOR THE PREPARATION OF TRANS-5-CHLORO-2-METHYL-2,3,3A,12B-TETRAHYDRO-1H-DIBENZ[2,3:6,7]-OXEPINO[4,5-C]PYRROLE | SCHERING CORPORATION | 2010-06-17 | — | — | US | disclosed |
| US-20100152461-A1 | INTERMEDIATE COMPOUNDS FOR THE PREPARATION OF TRANS-5-CHLORO-2-METHYL-2,3,3A,12B-TETRAHYDRO-1H-DIBENZ[2,3:6,7]-OXEPINO[4,5-C]PYRROLE | SCHERING CORPORATION | 2010-06-17 | — | — | US | disclosed |
| EP-2154134-A1 | Process for the preparation of trans-5-chloro-2-methyl-2,3,3a,12b-tetrahydro-1h-dibenz[2,3:6,7]oxepino[4,5-c]pyrrole. | N.V. Organon (NL) | 2010-02-17 | — | — | EP | disclosed |
| EP-1710241-B1 | Intermediate compounds for the preparation of trans-5-chloro-2-methyl-2,3,3a,12b-tetrahydro-1h-dibenz[2,3:6,7]oxepino[4,5-c]pyrrole | ORGANON NV (NL) | 2009-11-04 | — | — | EP | disclosed |
| US-20080214832-A1 | Process for making asenapine | SYNTHON BV (NL) | 2008-09-04 | — | — | US | disclosed |
| US-20080214832-A1 | Process for making asenapine | SYNTHON BV (NL) | 2008-09-04 | — | — | US | disclosed |
| WO-2008081010-A1 | PROCESS FOR MAKING ASENAPINE | SYNTHON B.V. (NL) | 2008-07-10 | — | — | WO | disclosed |
| US-20060229352-A1 | Intermediate compounds for the preparation of trans-5-chloro-2-methyl-2,3,3a,12b-tetrahydro-1H-dibenz[2,3:6,7]oxepino[4,5-c]pyrrole | ORGANON IRELAND LTD. (IE) | 2006-10-12 | — | — | US | disclosed |
| US-20060229352-A1 | Intermediate compounds for the preparation of trans-5-chloro-2-methyl-2,3,3a,12b-tetrahydro-1H-dibenz[2,3:6,7]oxepino[4,5-c]pyrrole | ORGANON IRELAND LTD. (IE) | 2006-10-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130211099-A1 | ASENAPINE MALEATE | CYP3A5, AANAT, ADRA2C | SLC6A4 17/4885SLC6A2 14/4885SLC6A3 49/4885 |
| US-20060229352-A1 | Intermediate compounds for the preparation of trans-5-chloro-2-methyl-2,3,3a,12b-tetrahydro-1H-dibenz[2,3:6,7]oxepino[4,5-c]pyrrole | DHPS, ODC1, OXTR | SLC6A4 3477/4885SLC6A2 3966/4885SLC6A3 1675/4885 |
| US-20100152461-A1 | INTERMEDIATE COMPOUNDS FOR THE PREPARATION OF TRANS-5-CHLORO-2-METHYL-2,3,3A,12B-TETRAHYDRO-1H-DIBENZ[2,3:6,7]-OXEPINO[4,5-C]PYRROLE | ODC1, DHPS, OXTR | SLC6A4 3467/4885SLC6A2 3875/4885SLC6A3 1508/4885 |
| US-20080214832-A1 | Process for making asenapine | CYP3A5, CYP3A4, CYP2C9 | SLC6A4 151/4885SLC6A2 247/4885SLC6A3 487/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.